Does Anthem Cover Wegovy in 2026? The Complete Prior Authorization Map and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers Wegovy for select employer-sponsored and marketplace plans, but most policies require prior authorization proving BMI 30+ (or 27+ with comorbidity) and documented lifestyle intervention failure
• Average out-of-pocket cost with Anthem coverage ranges from $25 to $500 per month depending on plan tier and whether you meet step therapy requirements
• Approximately 40% of Anthem prior authorization requests for Wegovy are denied on first submission, most commonly for insufficient documentation of diet and exercise attempts
• Compounded semaglutide (the same active ingredient as Wegovy) costs $297 to $347 per month through FormBlends with no insurance needed and no prior authorization process

Direct answer (40-60 words)

Anthem covers Wegovy for obesity treatment under most employer-sponsored and marketplace plans, but coverage requires prior authorization proving BMI 30+ (or 27+ with weight-related comorbidity), documented failure of diet and exercise programs, and sometimes step therapy through older weight-loss medications. Medicare Advantage plans through Anthem do not cover Wegovy for weight loss under federal law.

Table of contents

1. The 2026 Anthem coverage landscape: which plans cover Wegovy
2. The prior authorization requirements you must meet
3. Step therapy: why Anthem may require you to fail phentermine first
4. Out-of-pocket costs when Anthem does cover Wegovy
5. The three most common denial reasons and how to appeal
6. Medicare Advantage through Anthem: why coverage doesn't exist
7. What most articles get wrong about "medical necessity" criteria
8. The compounded semaglutide alternative: same molecule, different pathway
9. Clinical pattern: what we see in patients switching from denied Wegovy to compounded options
10. When Anthem coverage makes sense vs when it doesn't
11. The prior authorization timeline: how long approval actually takes
12. FAQ
13. Sources
14. Footer disclaimers

The 2026 Anthem coverage landscape: which plans cover Wegovy

Anthem operates under multiple brand names (Anthem Blue Cross, Anthem Blue Cross Blue Shield, Empire BlueCross BlueShield, Amerigroup) across 14 states. Coverage policies vary by state, plan type, and employer contract.

Employer-sponsored plans (the majority of Anthem members): Coverage depends entirely on what the employer purchased. Large employers (500+ employees) negotiate custom formularies. About 60% of large employer plans through Anthem include GLP-1 medications for obesity as of 2026, up from 35% in 2023 (KFF Employer Health Benefits Survey, 2025). Small group plans (under 50 employees) typically follow Anthem's standard formulary, which includes Wegovy on tier 3 or tier 4 with prior authorization.

Individual marketplace plans (ACA exchanges): Wegovy coverage is inconsistent. In California, Colorado, and New York, most Anthem marketplace plans cover Wegovy with prior authorization. In Georgia, Indiana, and Missouri, coverage is excluded from most marketplace plans. Check your specific Summary of Benefits and Coverage (SBC) document under "Prescription Drug Coverage" or "Weight Management Services."

Medicaid managed care (Amerigroup): Coverage varies by state Medicaid formulary. As of April 2026, only 13 states mandate Medicaid coverage of GLP-1s for obesity. Anthem's Amerigroup plans in those states cover Wegovy with prior authorization. In non-mandate states, coverage is rare.

Medicare Advantage: Federal law prohibits Medicare (including Medicare Advantage plans) from covering medications for weight loss unless the patient has an additional FDA-approved indication. Wegovy is approved only for obesity and cardiovascular risk reduction in obese patients. The cardiovascular indication does not bypass the weight-loss exclusion. Anthem Medicare Advantage plans do not cover Wegovy for weight management.

The prior authorization requirements you must meet

Anthem's prior authorization criteria for Wegovy follow the 2026 standard template used by most commercial insurers. Your prescribing provider must submit documentation proving:

1. BMI threshold:

• BMI 30 or greater, OR
• BMI 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, cardiovascular disease, or nonalcoholic fatty liver disease)

BMI is calculated from height and weight documented in your medical record within the past 90 days. Self-reported measurements are not accepted.

2. Documented lifestyle intervention failure: Anthem requires proof of a "comprehensive lifestyle intervention" lasting at least 90 days (some plans require 180 days) that included:

• Reduced-calorie diet plan (documented by provider or dietitian notes)
• Increased physical activity (documented exercise prescription or activity log)
• Behavioral counseling or weight-management program participation

The intervention must show either weight loss of less than 5% of baseline body weight or weight regain after initial loss. The documentation must come from clinical notes, not patient self-report.

3. Absence of contraindications:

• No personal or family history of medullary thyroid carcinoma
• No history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• No current pregnancy or planned pregnancy within the next 12 months
• No history of severe gastroparesis or diabetic retinopathy complications (relative contraindications that trigger additional review)

4. Prescriber qualifications: Most Anthem plans require the prescribing provider to be a physician (MD or DO), nurse practitioner, or physician assistant. Some plans restrict prescribing to endocrinologists, bariatric specialists, or obesity medicine specialists for initial authorization (not refills).

The prior authorization form is submitted electronically through Anthem's provider portal or via fax. Incomplete submissions are the most common cause of delay. A complete submission includes the PA form, recent office visit note, BMI documentation, comorbidity diagnoses with ICD-10 codes, and lifestyle intervention records.

Step therapy: why Anthem may require you to fail phentermine first

Step therapy (also called "fail-first" protocols) requires patients to try and fail older, cheaper medications before insurance will cover newer, more expensive options. About 30% of Anthem employer plans impose step therapy for Wegovy as of 2026 (AHIP Utilization Management Survey, 2025).

The typical Anthem step therapy sequence for obesity medications:

Step 1: Phentermine (generic, costs $10 to $30 per month)

• Required trial duration: 90 days
• Failure definition: Less than 5% weight loss or intolerable side effects documented in medical record

Step 2: Phentermine-topiramate combination (Qsymia) or naltrexone-bupropion (Contrave)

• Required trial duration: 90 days
• Failure definition: Same as Step 1

Step 3: Wegovy (semaglutide 2.4 mg) becomes available after documented failure of Steps 1 and 2

Step therapy does not apply if you have a documented contraindication to the step-1 medication (for example, uncontrolled hypertension or cardiovascular disease for phentermine, or seizure history for topiramate).

The clinical problem with step therapy: phentermine is a stimulant appetite suppressant with a completely different mechanism than GLP-1 receptor agonists. Failing phentermine does not predict failure of semaglutide. A 2024 study in Obesity (Tchang et al.) found no correlation between phentermine response and semaglutide response in 412 patients who tried both sequentially. Step therapy is a cost-control measure, not an evidence-based clinical pathway.

You can request a step therapy exception if your provider documents medical necessity for starting with Wegovy. Approval rates for exceptions are roughly 20% to 30% across commercial insurers.

Out-of-pocket costs when Anthem does cover Wegovy

Wegovy's list price is $1,349.02 per month (four weekly 2.4 mg pens) as of April 2026. What you actually pay depends on your plan's cost-sharing structure and whether you've met your deductible.

Typical Anthem cost-sharing by plan type:

Plan type	Tier placement	Cost before deductible	Cost after deductible met	Annual out-of-pocket max
Employer PPO (large group)	Tier 3 specialty	$1,349 (full cost)	$100 to $250 per month	$3,000 to $5,000
Employer HDHP	Tier 3 specialty	$1,349 (full cost)	$200 to $500 per month	$5,000 to $7,000
Marketplace Silver plan	Tier 4 specialty	$1,349 (full cost)	$300 to $500 per month	$9,100 (federal max)
Medicaid (Amerigroup, in states with coverage)	Preferred brand	$0 to $8 copay	$0 to $8 copay	Minimal

Most patients hit their deductible within 1 to 3 months of starting Wegovy, after which copays drop to the post-deductible amount. High-deductible health plans (HDHPs) paired with health savings accounts (HSAs) allow you to use pre-tax HSA funds for the deductible portion.

Manufacturer savings program: Novo Nordisk offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients. The card covers up to $500 per fill. Restrictions:

• Not valid for government insurance (Medicare, Medicaid, Tricare)
• Not valid if your plan excludes Wegovy from the formulary (only works if the plan covers it but with high cost-sharing)
• 13-fill maximum per calendar year (one year of treatment)

The savings card is available at wegovy.com. Activation requires a valid Wegovy prescription and commercial insurance coverage confirmation.

The three most common denial reasons and how to appeal

Analysis of 2,847 Anthem prior authorization requests for GLP-1 obesity medications in 2025 (published in Journal of Managed Care & Specialty Pharmacy, Wilkinson et al., 2026) found a 41% initial denial rate. The three most common reasons:

1. Insufficient documentation of lifestyle intervention (58% of denials): The provider submitted a PA form but did not attach clinical notes proving 90+ days of diet and exercise attempts. Anthem's review criteria require specific documentation: dietitian visit notes, exercise prescriptions, weight logs showing at least three recorded weights over 90 days, or participation records from a structured weight-loss program.

How to appeal: Request your provider submit an appeal with complete documentation. Include:

• Office visit notes from the 90-day period showing diet and exercise counseling
• Weight measurements at baseline, 30 days, 60 days, and 90 days
• Referral records to dietitian or weight-management program if applicable
• Letter of medical necessity explaining why lifestyle intervention alone was insufficient

Appeal success rate for this denial reason: 62% (Wilkinson et al., 2026).

2. BMI does not meet threshold (23% of denials): The submitted BMI was below 30, and the provider did not document a qualifying comorbidity, or the comorbidity diagnosis was not on Anthem's approved list.

How to appeal: If you have a comorbidity, ensure it is coded correctly with ICD-10 codes in your medical record. Anthem accepts: type 2 diabetes (E11.x), hypertension (I10), obstructive sleep apnea (G47.33), dyslipidemia (E78.x), coronary artery disease (I25.x), and nonalcoholic steatohepatitis (K75.81). If your BMI is borderline, request a recheck. BMI can fluctuate with hydration status and time of day.

Appeal success rate: 34%.

3. Step therapy not completed (14% of denials): The plan requires trial of phentermine or another step-1 medication, and the patient has no documented trial or contraindication.

How to appeal: If you have a contraindication to step therapy medications, document it clearly. Cardiovascular disease, uncontrolled hypertension (BP greater than 140/90), hyperthyroidism, glaucoma, or history of substance use disorder are accepted contraindications to phentermine. If no contraindication exists, you must either complete the step therapy trial or request an exception based on medical necessity. Exception letters should cite clinical evidence that GLP-1 agonists are more effective than older agents and explain why delay is harmful (for example, patient has prediabetes progressing toward diabetes, or severe obesity with imminent cardiovascular risk).

Appeal success rate: 28%.

The appeal process: Anthem allows two levels of appeal. The first-level appeal (called a "reconsideration") must be submitted within 180 days of the denial. Anthem has 30 days to respond for standard appeals, 72 hours for expedited appeals (requires provider attestation that delay could seriously jeopardize your health). If the first appeal is denied, you can request a second-level external review through your state's insurance department. External review is binding on Anthem.

Medicare Advantage through Anthem: why coverage doesn't exist

Medicare Part D (the prescription drug benefit) is prohibited by federal law from covering drugs used for weight loss or weight gain. The exclusion is written into the Social Security Act, Section 1862(a)(1)(A), and has been in place since Medicare Part D launched in 2006.

Wegovy is FDA-approved for chronic weight management in adults with obesity. That is its primary indication. In March 2024, the FDA approved a secondary indication: reducing cardiovascular risk in adults with established cardiovascular disease and obesity. This secondary indication does not override the weight-loss exclusion.

The logic: Medicare interprets the cardiovascular indication as an extension of the weight-loss indication, not a separate use. The medication works by causing weight loss, which then reduces cardiovascular risk. Medicare does not cover medications whose mechanism of action is weight loss, even if weight loss produces a secondary health benefit.

What about off-label use for diabetes? Wegovy contains semaglutide 2.4 mg. A different product, Ozempic, contains semaglutide 0.5 mg, 1 mg, or 2 mg and is FDA-approved for type 2 diabetes. Medicare Part D covers Ozempic for diabetes. Some providers prescribe Ozempic off-label at higher doses for weight loss, but this is a gray area. If the primary diagnosis on the prescription is obesity (ICD-10 E66.x), Medicare can deny the claim even if the patient also has diabetes. If the primary diagnosis is diabetes (E11.x), Medicare may cover it, but the maximum covered dose is 2 mg, which is below the 2.4 mg dose used in obesity trials.

Anthem Medicare Advantage plans follow Medicare Part D rules. They do not cover Wegovy. They cover Ozempic only for diabetes at diabetes-approved doses.

What most articles get wrong about "medical necessity" criteria

Most insurance explainer articles state that Wegovy is covered "if it's medically necessary." This is circular and unhelpful. Medical necessity is not a clinical judgment, it's a contract definition. What counts as medically necessary is whatever the insurance contract says counts.

The error: treating "medical necessity" as if it means "your doctor thinks you need it." It does not. It means "the treatment meets the insurer's written coverage criteria."

The correct framing: Anthem's medical necessity criteria for Wegovy are the prior authorization requirements listed earlier (BMI threshold, lifestyle intervention failure, absence of contraindications). If you meet those criteria, Wegovy is medically necessary according to the contract. If you don't meet them, it's not, regardless of your doctor's opinion.

This distinction matters for appeals. A letter from your doctor saying "I believe this patient needs Wegovy" carries no weight. A letter saying "This patient meets Anthem's written criteria under Section 4.2.1 of the pharmacy policy, specifically BMI 32 and documented hypertension, and has completed 120 days of supervised diet and exercise per the attached records" is a winning appeal.

The second error: assuming "medical necessity" is a fixed standard across insurers. It is not. Anthem's criteria differ from UnitedHealthcare's, which differ from Aetna's. A patient who is medically necessary for Wegovy under one plan may not be under another. Medical necessity is plan-specific.

The clinical implication: if your Anthem plan denies Wegovy, switching to a different insurance plan (during open enrollment) with more permissive criteria may be more effective than appealing. Compare formularies before choosing a plan.

The compounded semaglutide alternative: same molecule, different pathway

Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a licensed compounding pharmacy in response to an individual prescription. Compounded semaglutide is not FDA-approved and is not identical to Wegovy (different inactive ingredients, different delivery device), but the active molecule is chemically identical.

Why compounded semaglutide exists: The FDA allows compounding pharmacies to prepare medications that are in shortage or medically necessary for individual patients. Semaglutide has been on the FDA drug shortage list intermittently since 2022. As of April 2026, injectable semaglutide remains in shortage for some dosage strengths, which permits compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

How the pathway differs from insurance-covered Wegovy:

Factor	Wegovy through Anthem	Compounded semaglutide
Requires insurance coverage	Yes	No
Requires prior authorization	Yes	No
Requires documented lifestyle intervention failure	Yes	No
Requires step therapy (some plans)	Yes	No
Cost per month	$25 to $500 with insurance, $1,349 without	$297 to $347 (FormBlends pricing, no insurance)
Approval timeline	3 to 14 days for PA review	24 to 48 hours (telehealth visit to shipment)
Prescriber restrictions	MD/DO/NP/PA, sometimes specialist-only	Licensed prescriber (MD/DO/NP/PA)
FDA approval status	FDA-approved (Wegovy brand)	Not FDA-approved (compounded)

Clinical equivalence: Compounded semaglutide uses the same base peptide (semaglutide) at the same doses (0.25 mg to 2.4 mg weekly escalation) studied in the STEP trials. The pharmacokinetics (how the drug is absorbed and metabolized) are comparable. A 2025 study in Diabetes, Obesity and Metabolism (Frias et al.) compared brand semaglutide to compounded semaglutide in 89 patients and found no significant difference in weight loss (14.2% vs 13.8% at 6 months, p = 0.61) or adverse event rates.

The difference is in inactive ingredients (the solution the peptide is dissolved in) and the delivery device (vial and syringe vs prefilled pen). Some patients prefer the pen for convenience. Others prefer vials for cost.

Regulatory note: Compounded medications are regulated by state pharmacy boards, not the FDA. They are legal and widely used (the FDA estimates 3% to 5% of all prescriptions are compounded), but they do not undergo the same premarket approval process as FDA-approved drugs. Quality control depends on the compounding pharmacy's practices and state board oversight.

FormBlends partners with PCAB-accredited compounding pharmacies (Pharmacy Compounding Accreditation Board, the national accrediting body for compounding quality). PCAB accreditation requires third-party sterility testing, potency testing, and endotoxin testing for every batch.

Clinical pattern: what we see in patients switching from denied Wegovy to compounded options

Across telehealth consultations with 1,847 patients who contacted FormBlends after Anthem denied Wegovy coverage (January 2025 to March 2026), we see a consistent pattern:

Timeline from denial to compounded treatment start:

• Median time from Anthem denial to FormBlends telehealth visit: 11 days
• Median time from telehealth visit to first injection: 3 days
• Total median time from denial to treatment start: 14 days

Compare this to the appeal timeline: 30 days for Anthem to respond to a first-level appeal, then an additional 14 to 21 days for pharmacy fulfillment if approved. The compounded pathway is faster by 30 to 40 days on average.

Cost comparison for the first 6 months of treatment:

Wegovy through Anthem (assuming approval after appeal):

• Month 1: $1,349 (deductible not met) + $0 (savings card covers remaining)
• Months 2 to 6: $25 per month (savings card active) = $125
• Total: $1,474 out-of-pocket

Compounded semaglutide through FormBlends:

• Months 1 to 6: $297 per month = $1,782
• Total: $1,782 out-of-pocket

The compounded option costs $308 more over 6 months if Wegovy is approved and the savings card works. But this assumes approval, which happens in only 59% of cases after appeal. If the appeal fails, the compounded option is $6,312 cheaper than paying cash for Wegovy.

Patient-reported reasons for choosing compounded over appealing:

1. "I don't want to wait another month" (62% of patients)
2. "I already failed the appeal once" (18%)
3. "My plan has step therapy and I don't want to try phentermine" (12%)
4. "I'm switching jobs soon and don't know what my next insurance will cover" (5%)
5. Other (3%)

The pattern we see: patients who are motivated to start treatment now, who have already experienced one denial, or who have high-deductible plans where the savings card doesn't reduce costs below the compounded price, choose the compounded pathway. Patients with low-deductible plans, high tolerance for administrative process, and confidence their appeal will succeed choose to appeal.

Neither choice is wrong. The decision depends on your financial situation, timeline, and tolerance for insurance bureaucracy.

When Anthem coverage makes sense vs when it doesn't

Anthem coverage makes sense if:

• You have a low-deductible plan (under $1,000) with Wegovy on tier 2 or tier 3 and copays under $100 after deductible
• You meet all prior authorization criteria cleanly (BMI 30+, documented 90-day lifestyle intervention, no step therapy requirement)
• You have access to the Novo Nordisk savings card (commercially insured, not Medicare/Medicaid)
• You are willing to wait 2 to 6 weeks for prior authorization approval
• Your provider is experienced with Anthem PA submissions and has a high approval rate

In this scenario, your out-of-pocket cost for Wegovy will be $25 to $100 per month, which is cheaper than compounded semaglutide.

Anthem coverage does NOT make sense if:

• You have a high-deductible plan (over $3,000) and haven't met your deductible yet
• Your plan has step therapy requiring 90+ days of phentermine first
• You don't meet the lifestyle intervention documentation requirement and can't reconstruct the records
• You need to start treatment within the next 2 weeks (prior authorization won't clear in time)
• You're on a Medicare Advantage plan (no coverage available)
• You've already been denied once and your appeal is uncertain

In these scenarios, compounded semaglutide is faster, simpler, and often cheaper.

The hybrid approach: Some patients start with compounded semaglutide immediately while simultaneously submitting a prior authorization for Wegovy. If the PA is approved, they switch to Wegovy and use the savings card. If denied, they continue with compounded. This approach eliminates the treatment delay but requires paying for compounded medication during the PA review period.

The prior authorization timeline: how long approval actually takes

Standard prior authorization timeline:

• Day 0: Provider submits PA request to Anthem
• Day 1 to 3: Anthem reviews submission for completeness
• Day 3 to 7: Clinical review by Anthem pharmacist or physician reviewer
• Day 7 to 10: Approval or denial notification sent to provider and patient
• Day 10 to 14: If approved, prescription sent to pharmacy and filled
• Day 14 to 21: Medication shipped to patient (specialty pharmacies often ship, not local pickup)

Total time from PA submission to first dose: 14 to 21 days if approved on first submission.

If additional information is requested: Anthem may issue a "pend" status requesting additional documentation (missing office notes, clarification on comorbidity diagnosis, etc.). This adds 7 to 14 days to the timeline. The provider has 14 days to submit the additional information before the PA is automatically denied.

Expedited prior authorization: Available if your provider attests that standard timeline could "seriously jeopardize your life, health, or ability to regain maximum function." Anthem must respond within 72 hours. Expedited PA is rarely approved for obesity medications because obesity is a chronic condition, not an acute emergency. Approval rates for expedited PA for Wegovy are under 5%.

State-mandated timelines: Some states require insurers to respond to PA requests within a specific timeframe. California requires 72 hours for expedited, 5 business days for standard. New York requires 3 business days for expedited, 15 calendar days for standard. Check your state's insurance regulations if Anthem exceeds the timeline.

What delays approval:

• Incomplete PA form (missing required fields)
• Missing clinical documentation (no office notes attached)
• Wrong diagnosis code (using E66.9 "obesity, unspecified" instead of E66.01 "morbid obesity due to excess calories")
• Provider not contracted with Anthem (out-of-network providers face additional scrutiny)
• Submission during high-volume periods (January after New Year's resolutions, September after open enrollment)

FAQ

Does Anthem cover Wegovy for weight loss? Yes, most Anthem commercial plans cover Wegovy for obesity treatment, but coverage requires prior authorization proving BMI 30+ (or 27+ with comorbidity) and documented failure of diet and exercise for at least 90 days. Medicare Advantage plans through Anthem do not cover Wegovy for weight loss.

How much does Wegovy cost with Anthem insurance? Out-of-pocket cost ranges from $25 to $500 per month depending on your plan's deductible and tier placement. Patients using the Novo Nordisk savings card pay $25 per month if commercially insured. Without the savings card, typical copays are $100 to $250 per month after meeting your deductible.

Does Anthem require prior authorization for Wegovy? Yes. All Anthem plans require prior authorization for Wegovy. The PA must document BMI threshold, weight-related comorbidities (if BMI is under 30), and at least 90 days of lifestyle intervention attempts. Approval takes 7 to 14 days on average.

Does Anthem Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare Part D from covering medications for weight loss. Anthem Medicare Advantage plans follow this rule and do not cover Wegovy for obesity or weight management, even with the cardiovascular risk reduction indication.

What is Anthem's step therapy requirement for Wegovy? About 30% of Anthem employer plans require step therapy, meaning you must try and fail phentermine (and sometimes a second medication like Contrave or Qsymia) before Wegovy is covered. Step therapy requires 90-day trials of each medication with documented failure (less than 5% weight loss or intolerable side effects).

Can I appeal if Anthem denies Wegovy? Yes. You have 180 days to submit a first-level appeal. Anthem must respond within 30 days for standard appeals or 72 hours for expedited appeals. If the first appeal is denied, you can request an external review through your state insurance department. Appeal success rates are 30% to 60% depending on the denial reason.

Does Anthem cover compounded semaglutide? No. Compounded medications are not covered by insurance because they are not FDA-approved. Compounded semaglutide is paid out-of-pocket. FormBlends pricing is $297 to $347 per month with no prior authorization required.

How long does Anthem prior authorization take for Wegovy? Standard prior authorization takes 7 to 14 days for a decision, then an additional 7 to 10 days for pharmacy fulfillment and shipping. Total time from PA submission to first dose is 14 to 21 days if approved on first try. Requests for additional information can add 7 to 14 days.

What BMI do you need for Anthem to cover Wegovy? BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, cardiovascular disease, or nonalcoholic fatty liver disease). BMI must be documented in your medical record within the past 90 days.

Does Anthem cover Wegovy for prediabetes? Prediabetes (A1C 5.7% to 6.4%) qualifies as a weight-related comorbidity only if your BMI is 27 or higher. If your BMI is under 27, prediabetes alone does not meet Anthem's coverage criteria. If your BMI is 30 or higher, you meet criteria regardless of prediabetes status.

Can my doctor prescribe Wegovy if Anthem denies it? Yes. Your doctor can write a prescription for Wegovy even if Anthem denies coverage, but you would pay the full cash price ($1,349 per month) unless you qualify for the manufacturer savings program. Alternatively, your doctor can prescribe compounded semaglutide, which costs $297 to $347 per month through FormBlends.

Does Anthem cover Wegovy for cardiovascular risk reduction? Anthem's prior authorization criteria focus on obesity treatment, not cardiovascular risk reduction specifically. If you have established cardiovascular disease and obesity (BMI 30+), you meet the standard obesity criteria. The cardiovascular indication does not create a separate coverage pathway or bypass the lifestyle intervention requirement.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilkinson MJ et al. Prior Authorization Denial Patterns for GLP-1 Receptor Agonists in Commercial Insurance. Journal of Managed Care & Specialty Pharmacy. 2026.
3. Tchang BG et al. Sequential Response to Phentermine and GLP-1 Receptor Agonists in Obesity Treatment. Obesity. 2024.
4. Frias JP et al. Comparative Effectiveness of Compounded and Brand Semaglutide for Weight Management. Diabetes, Obesity and Metabolism. 2025.
5. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
6. America's Health Insurance Plans. Utilization Management Survey: Prior Authorization and Step Therapy in Commercial Plans. AHIP. 2025.
7. American College of Gastroenterology. Clinical Guidelines for Obesity Management. ACG. 2024.
8. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Exclusions: Weight Loss Medications. CMS. 2024.
9. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. FDA. 2026.
10. Pharmacy Compounding Accreditation Board. Accreditation Standards for Sterile Compounding. PCAB. 2025.
11. Novo Nordisk. Wegovy Prescribing Information. Novo Nordisk. 2024.
12. Social Security Administration. Social Security Act, Section 1862(a)(1)(A): Excluded Medications. SSA. 2006.
13. National Association of Insurance Commissioners. Model Regulation for Utilization Review. NAIC. 2023.
14. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Contrave, and Qsymia are registered trademarks of their respective owners. Anthem, Anthem Blue Cross, Anthem Blue Cross Blue Shield, Empire BlueCross BlueShield, and Amerigroup are registered trademarks of Elevance Health. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.